Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. Now the FDA has ...

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and ...

Sleep apnea device maker ResMed will expand its American manufacturing operations and open a new facility in Indianapolis in 2027 but says it is not due to pressure from President Donald Trump for ...

ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of ...

ResMed’s 2030 strategy focuses on empowering 500 million lives by the end of the decade through its digital health products and cloud-based software solutions. The company reported that it has already ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

ResMed, an ASX healthcare leader, is well-positioned to capitalise on the growing demand for sleep apnoea treatment and digital health solutions, offering potential long-term rewards. The company's ...

ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.

The New York Stock Exchange-listed ResMed Inc (NYSE: RMD) share price surged more than 3% overnight on Wall Street, bringing the dual-listed sleep tech company within striking distance of its all-time ...

ResMed Inc. (NYSE:RMD) Q4 2025 Earnings Call Transcript July 31, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.55, expectations were $2.49. Operator: Hello, and welcome to the Q4 ...

Shares of medical device company ResMed (NYSE:RMD) jumped 3.1% in the afternoon session after the company reported strong fourth-quarter financial results that surpassed analyst estimates. The medical ...

Resmed announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the market closes. Following the release, management will ...